Market closedNon-fractional
Cidara Therapeutics/CDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
CDTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
69
Website
www.cidara.com
CDTX Metrics
BasicAdvanced
$55M
Market cap
-
P/E ratio
-$8.02
EPS
1.11
Beta
-
Dividend rate
Price and volume
Market cap
$55M
Beta
1.11
Financial strength
Current ratio
0.716
Quick ratio
0.555
Long term debt to equity
-17.902
Total debt to equity
-26.136
Management effectiveness
Return on assets (TTM)
-35.29%
Return on equity (TTM)
-800.93%
Valuation
Price to revenue (TTM)
1.168
Price to book
-2.8
Price to tangible book (TTM)
-2.8
Price to free cash flow (TTM)
-2.904
Growth
Revenue change (TTM)
-44.56%
Earnings per share change (TTM)
124.97%
3-year revenue growth (CAGR)
57.04%
3-year earnings per share growth (CAGR)
-38.66%
What the Analysts think about CDTX
Analyst Ratings
Majority rating from 5 analysts.
CDTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.4M
-52.00%
Net income
-$10M
83.93%
Profit margin
-122.61%
283.16%
CDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.80
-$1.80
-$0.80
-$2.28
-
Expected
-$2.60
-$3.25
-$2.07
-$0.20
-$4.10
Surprise
7.69%
-44.62%
-61.29%
1,040.00%
-
CDTX News
AllArticlesVideos
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
GlobeNewsWire·2 months ago
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $55M as of July 27, 2024.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of July 27, 2024.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cidara Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.